Welcome!

News Feed Item

Antibody Drug Conjugates: Contract Manufacturing Market, 2014-2024

NEW YORK, March 24, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Antibody Drug Conjugates: Contract Manufacturing Market, 2014-2024
http://www.reportlinker.com/p02016141/Antibody-Drug-Conjugates-Contract-Manufacturing-Market-2014-2024.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Manufacturing

INTRODUCTION

The concept of Antibody drug conjugates (ADCs) is simple - a cytotoxic / chemotherapy drug is delivered to the target tissue through linking it with a monoclonal antibody. However, the practical challenge of manufacturing such complex and highly toxic molecules is huge.

The multi-component aspect of ADCs deems it necessary to have both biologic and high-potency facilities. Despite the fact that this new class of therapeutic agents is gaining increased attention from both small and large pharmaceutical companies, in-house manufacturing capabilities for these molecules are rare. Most of the companies have a limited number of ADCs under development. Considering the utilisation rates are likely to be low in the near future, the investment required for setting up such high-containment biologic facilities is a huge financial risk.

As such, majority of the work is currently being outsourced to specialist CMOs focused on one or more areas of ADC manufacturing. The last one year has witnessed a surge in investments from the CMOs for facility expansions. Such investment decisions have been driven by an increase in the demand for ADC production services from drug developers. Although, there are only three marketed ADCs till date, a rich and growing pipeline is a very big opportunity for the contract manufacturers.

SCOPE OF THE REPORT

The "ADC Contract Manufacturing Market, 2014-2024" report provides an extensive study of the contract manufacturing opportunity for this emerging class of therapeutics. The report covers various aspects and identifies the CMOs active in this space, their capabilities with respect to ADCs, available capacity (clinical / commercial) for bio-conjugation and geographic location / spread of the facilities. One of the key objectives of this report is to understand the current state and future potential for CMOs in the market. This is done by analysing

- The rich pipeline of ADC therapeutics,
- In-house / contract manufacturing status of various components of phase II, phase III and marketed ADCs,
- Commercial sales potential for various ADC molecules under development, and
- Likely outsourcing profile across various steps involved in ADC manufacturing

The base year for the report is 2013. The report provides short-mid term and long term market forecasts for the period 2013 - 2018 and 2019 - 2024, respectively. We have discussed, in detail, the key drivers behind the growth of this market. The estimated sales figures of the ADC therapeutics market forms the basis for our analysis of the forecasted revenues for CMOs. Any changes in the ADC market and its growth are likely to alter the outsourcing activity in the market.

To add robustness to our forecast model, we have provided three market scenarios which vary in terms of the overall commercial sales and the likely cost of manufacturing. The conservative, base and optimistic scenarios represent three different tracks of market evolution.

All actual figures have been sourced and analysed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS

1. Only a few ADC developers have in-house manufacturing facilities; majority of the companies, including the leading technology providers (Seattle Genetics and ImmunoGen) are dependent on contract manufacturers to supply the components.
2. Discussions with senior experts in the industry reveal that around 70%-80% of ADC manufacturing is outsourced.
3. Manufacturing of ADCs poses significant challenges due to nature of these molecules. Managing the supply chain and working with multiple CMOs adds to the complexity of the manufacturing process; one-stop-shops are rarity in this field
4. The overall market for contract manufacturing of ADCs is likely to exceed the 1 billion dollar mark in the coming decade; the presence of both large and small biotech companies is funding the growing pipeline of ADCs.
5. Numerous partnership opportunities exist for CMOs to bring together their complementary skills; such partnerships will enable further advancements in this field without significantly enhancing the capital exposure.

RESEARCH METHODOLOGY

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
- Annual reports
- Investor presentations
- SEC filings
- Industry databases
- News releases from company websites
- Government policy documents
- Other analysts' opinion reports

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES

Chapter 2 provides the executive summary of the insights captured during our research. The summary offers a high level view on where the ADC contract manufacturing market is headed in the mid-long term.

Chapter 3 provides a general introduction to antibody drug conjugates. We have discussed in detail the components of an ADC. In addition, we have highlighted the advantages of ADC as a therapeutic drug over traditional treatments.

Chapter 4 explores the existing ADC therapeutics, both commercial and under development. Furthermore, we have analysed the ADC market from the point of view of the commonly used linkers and cytotoxins.

Chapter 5 presents our analysis of the in-house and contract manufacturing of ADCs. There is special focus on CMOs with capabilities to carry out the different steps in ADC manufacturing.

Chapter 6 highlights the regional landscape of CMOs manufacturing components of ADC, conducting conjugation or fill/finish. The analysis has been done by looking at the location of CMOs facilities where these activities are handled.

Chapter 7 includes profiles of some of the CMOs in the ADC market. Each company profile includes information such as financial performance, geographical presence, recent investments for ADC manufacturing and future plans.

Chapter 8 presents our analysis of the current and potential future market (in terms of value) for contract manufacturing of ADCs. We have presented the market data for base year 2013 and our forecasts for the period 2014 - 2024. The chapter includes, in detail, our revenue forecast for manufacturing antibody, drug-linker, conjugation, fill/finish and other components involved in ADC production.

Chapter 9 provides our analysis of the strengths, weaknesses, opportunities and threats in the ADC contract manufacturing market. This section captures the key elements likely to influence future growth.

Chapter 10 includes five interview transcripts based on our discussion with some of the leading CMOs in the ADC manufacturing market. The CMOs interviewed include Catalent, BSP Pharmaceuticals, Lonza and Piramal Healthcare. One additional CMO which was interviewed requested the details to be published as anonymous.

Chapter 11 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 12 and Chapter 13 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.

TABLE OF CONTENTS

1. PRELUDE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Parts of an ADC
3.3. ADCs: The Revolutionary Technology
3.4. The Traditional Treatments: Naked Antibody and Cytotoxins
3.4.1. Naked Antibodies
3.4.1.1. How Monoclonal Antibody Therapy Works
3.4.2. Cytotoxins
3.5. Conjugated or Armed Antibodies
3.6. Advantages of ADCs over Traditional Therapeutics
3.7. Steps Involved in Manufacturing an ADC

4. ADC THERAPEUTICS: DEVELOPMENT OVERVIEW
4.1. Chapter Overview
4.2. Three ADCs In the Market
4.3. Analysis of the Development Pipeline
4.3.1. Limited Number of Molecules in Late Stage Development
4.4. Commonly Used Cytotoxins in ADC
4.4.1. Cytotoxins Used in ADCs are Highly Potent APIs
4.4.2. Auristatins are the Most Commonly Used Cytotoxins
4.5. Linker: Function and Types
4.5.1. Manufacturing of Linkers
4.5.2. ADC Market by Type of Linker

5. MANUFACTURING OF ADCs: A MARKET OVERVIEW
5.1. Chapter Overview
5.2. Challenges Facing the ADC Manufacturers
5.3. In-House Manufacturing of ADCs
5.4. Majority of ADC Contract Manufacturing is Currently Outsourced
5.5. Presence of Contract Manufacturers
5.5.1. Investment From All Fronts
5.5.2. Start-ups for Contract Manufacturing of ADCs
5.5.3. Contract Manufacturers Collaborating to Provide ADC Capabilities
5.5.3.1. CMOs Partnering With ADC Technology Providers to Offer Site-Specific Conjugation
5.5.4. CMOs Manufacturing Linkers
5.5.5. CMOs with HPAPI / Cytotoxic Capabilities
5.5.6. Limited Conjugation Capability
5.5.7. Lack of Full Service Providers For ADCs

6. CMOs: WORLDWIDE LANDSCAPE
6.1. Unlike APIs, HPAPIs are Mainly Manufactured in Developed Countries
6.2. Lack of Commercial Scale Conjugation Service Providers In The US
6.3. Cytotoxic Fill/Finish: A Gap in the US

7. PROFILES OF LEADING COMPANIES
7.1. Chapter Overview
7.2. Sigma-Aldrich Fine Chemicals (SAFC)
7.2.1. Financial Performance
7.2.2. SAFC Commercial: The ADC Manufacturer
7.2.3. ADC Contract Manufacturing Plants
7.2.4. Recent Investments for ADC Manufacturing
7.2.5. ADC Manufacturing Experience
7.3. Lonza
7.3.1. Financial Performance
7.3.2. ADC Capabilities
7.3.2.1. ADC Manufacturing Plant
7.3.3. ADC Manufacturing Experience
7.3.4. Recent Investment in ADC Production
7.4. Piramal Healthcare Pharma Solutions
7.4.1. Financial Performance
7.4.2. Piramal Healthcare Pharma Solutions: FY2013 Performance
7.4.3. ADC Manufacturing Capability
7.4.4. ADC Manufacturing Experience
7.4.4.1. Investment for ADC Production
7.4.5. Collaboration with Fujifilm Diosynth Biotechnologies
7.5. Albany Molecular Research (AMRI Global)
7.5.1. Financial Performance
7.5.2. ADC Capabilities And Experience
7.6. BSP Pharmaceuticals
7.6.1. Manufacturing Plant
7.6.2. ADC Capabilities
7.6.3. ADC Experience
7.6.4. Recent Investments And Future Plans
7.7. Pierre Fabre Laboratories
7.7.1. Financial Performance
7.7.2. Pierre Fabre Medicament Production (PFMP) / Aquitaine Pharm International
7.7.3. ADC Capabilities
7.7.4. Cytotoxic Drugs Experience
7.8. Catalent Pharma Solutions
7.8.1. Financial Performance
7.8.2. Entry in to the ADC Market: Collaboration with Redwood Biosciences
7.8.3. ADC Manufacturing Capability

8. MARKET SIZE AND FORECAST
8.1. Chapter Overview
8.2. Forecast Methodology
8.3. The ADC Drug Sales Market, 2012 - 2024
8.4. ADC Contract Manufacturing Market, 2012 - 2024
8.4.1. Background
8.4.2. Key Drivers
8.4.3. Overall CMO Market Forecast (Base Scenario), 2013 - 2024
8.4.4. CMO Forecast: Antibody (Base Scenario), 2013- 2024
8.4.5. CMO Forecast: Drug/Linker (Base Scenario), 2013 - 2024
8.4.6. CMO Forecast: Conjugation (Base Scenario), 2013 - 2024
8.4.7. CMO Forecast: Fill/Finish (Base Scenario), 2013 - 2024
8.4.8. CMO Forecast: Other Activities (Base Scenario), 2013 - 2024

9. SWOT ANALYSIS
9.1. Chapter Overview
9.2. Strengths
9.2.1. Large Pharmaceutical Companies Funding the Growing Pipeline
9.2.2. Presence of Small / Start-Up Biotechnology Companies
9.2.3. Multiple Components of an ADC
9.3. Weaknesses
9.3.1. Association with Multiple CMOs
9.3.2. Final ADCs are Often Heterogeneous
9.4. Opportunities
9.4.1. Site-Specific Conjugation
9.4.2. Partnering Opportunities
9.5. Threats
9.5.1. In-house Manufacturing of ADCs
9.5.2. High Failure Rate May Lessen the Confidence in Technology
9.5.3. The Scale of Manufacturing: A Prospective Bottleneck

10. INTERVIEW TRANSCRIPTS
10.1. Interview 1: Piramal Healthcare, Dr. Mark Wright (Site Head, Grangemouth)
10.2. Interview 2: Leading CMO (Director, Business Development)
10.3. Interview 3: Lonza, Laurent Ducry (ADC R&D)
10.4. Interview 4: Catalent Pharma Solutions, Stacy McDonald (Group Product Manager) & Jennifer L. Mitcham (Director - Business Development)
10.5. Interview 5: BSP Pharmaceuticals, Aldo Braca (CEO)

11. CONCLUSION
11.1. Outsourcing Trend Likely to Strengthen Further
11.2. ADC Manufacturing: A Need – Gap Analysis
11.3. CMO Market will Grow as ADCs Move From Pipeline to Market
11.4. Concluding Remarks

12. LIST OF COMPANIES AND ORGANISATIONS

13. TABLES

LIST OF FIGURES

Figure 3.1 Parts of Antibody Drug Conjugate
Figure 4.1 ADCs in Clinical Development: Share (%) by Phase of Development
Figure 4.2 ADCs in Clinical Development: Share (%) by Cytotoxin Used
Figure 5.1 ADCs: Matrix View of Outsourced Activities by Company
Figure 6.1 ADC HPAPI: Worldwide CMO Facilities
Figure 6.2 HPAPI / Cytotoxic Manufacturing Facilities: Regional Evaluation by Number of Facilities
Figure 6.3 ADC Conjugation: Worldwide CMO Facilities
Figure 6.4 ADC Fill / Finish: Worldwide CMO Facilities
Figure 7.1 SAFC: Revenues, FY 2012 (USD MM)
Figure 7.2 SAFC Commercial: Revenues, FY 2012 (USD MM)
Figure 7.3 Lonza: Revenues, FY 2012 (USD MM)
Figure 7.4 Piramal Enterprises: Revenues, FY 2013 (USD MM)
Figure 7.5 Piramal Healthcare Pharma Solutions: Revenues, FY 2013 (USD MM)
Figure 7.6 AMRI Global: Revenues, FY 2012 (USD MM)
Figure 7.7 Pierre Fabre Laboratories: Revenues, FY 2012 (USD MM)
Figure 7.8 Catalent: Revenues, FY 2013 (USD MM)
Figure 8.1 ADC Sales Forecast, 2012 - 2024: Base Scenario (USD MM)
Figure 8.2 ADCs: Cost of Manufacturing
Figure 8.3 ADCs: Level of Outsourcing
Figure 8.4 ADC Contract Manufacturing Market, 2013 - 2024: Base Scenario (USD MM)
Figure 8.5 ADC Outsourcing: Evolving Landscape
Figure 8.6 CMO Forecast: Antibody, 2013 - 2024: Base Scenario (USD MM)
Figure 8.7 CMO Forecast: Drug/Linker, 2013 - 2024: Base Scenario (USD MM)
Figure 8.8 CMO Forecast: Conjugation, 2013 - 2024: Base Scenario (USD MM)
Figure 8.9 CMO Forecast: Fill/Finish, 2013 - 2024: Base Scenario (USD MM)
Figure 8.10 CMO Forecast: Other Activities, 2013 - 2024: Base Scenario (USD MM)
Figure 11.1 ADC Contract Manufacturing Market, 2014, 2019, 2024 (USD MM)
Figure 11.2 ADC Manufacturing: The Driving Forces

LIST OF TABLES

Table 4.1 ADC Molecules in Clinical Development – Roche / Genentech
Table 4.2 ADC Molecules in Clinical Development – Seattle Genetics
Table 4.3 ADC Molecules in Clinical Development – ImmunoGen
Table 4.4 ADC Molecules in Clinical Development – Immunomedics
Table 4.5 ADC Molecules in Clinical Development – Astellas Pharma / Agensys
Table 4.6 ADC Molecules in Clinical Development – Pfizer / Wyeth
Table 4.7 ADC Molecules in Clinical Development – Sanofi Aventis
Table 4.8 ADC Molecules in Clinical Development – Amgen
Table 4.9 ADC Molecules in Clinical Development – AbbVie
Table 4.10 ADC Molecules in Clinical Development – Millenium
Table 4.11 ADC Molecules in Clinical Development – Celldex Therapeutics
Table 4.12 ADC Molecules in Clinical Development – Progenics Pharmaceuticals
Table 4.13 ADC Molecules in Clinical Development – Genmab
Table 4.14 ADC Molecules in Clinical Development – Bayer Healthcare
Table 4.15 ADC Molecules in Clinical Development – Biotest
Table 4.16 ADC Molecules in Clinical Development – Bristol-Myers Squibb
Table 4.17 ADC Molecules in Clinical Development – Stem CentRx
Table 4.18 ADC Molecules in Clinical Development – Undisclosed
Table 4.19 ADC Molecules in Preclinical Development – Ambrx
Table 4.20 ADC Molecules in Preclinical Development – Oxford BioTherapeutics
Table 4.21 ADC Molecules in Preclinical Development – Novartis
Table 4.22 ADC Molecules in Preclinical Development – Roche / Genentech
Table 4.23 ADC Molecules in Preclinical Development – Sanofi Aventis
Table 4.24 ADC Molecules in Preclinical Development – Amgen
Table 4.25 ADC Molecules in Preclinical Development – Synthon
Table 4.26 ADC Molecules in Preclinical Development – AbbVie
Table 4.27 ADC Molecules in Preclinical Development – AbGenomics
Table 4.28 ADC Molecules in Preclinical Development – ADC Therapeutics
Table 4.29 ADC Molecules in Preclinical Development – Affinicon
Table 4.30 ADC Molecules in Preclinical Development – Allozyne
Table 4.31 ADC Molecules in Preclinical Development – Avid Biologics
Table 4.32 ADC Molecules in Preclinical Development – Astellas
Table 4.33 ADC Molecules in Preclinical Development – Bayer
Table 4.34 ADC Molecules in Preclinical Development – Bristol Myers Squibb
Table 4.35 ADC Molecules in Preclinical Development – Celldex Therapeutics
Table 4.36 ADC Molecules in Preclinical Development – Daiichi Sankyo
Table 4.37 ADC Molecules in Preclinical Development – Eli Lilly
Table 4.38 ADC Molecules in Preclinical Development – Endo Pharmaceuticals
Table 4.39 ADC Molecules in Preclinical Development – Esperance Pharmaceuticals
Table 4.40 ADC Molecules in Preclinical Development – GSK
Table 4.41 ADC Molecules in Preclinical Development – Intellect Neurosciences
Table 4.42 ADC Molecules in Preclinical Development – Merck
Table 4.43 ADC Molecules in Preclinical Development – National Research Council, Canada
Table 4.44 ADC Molecules in Preclinical Development – Pfizer
Table 4.45 ADC Molecules in Preclinical Development – Philochem
Table 4.46 ADC Molecules in Preclinical Development – Seattle Genetics
Table 4.47 ADC Molecules in Preclinical Development – Undisclosed
Table 4.48 Some Commonly Used Cytotoxins for ADC Therapeutics
Table 4.49 OEL Bands, Safebridge Consultants
Table 4.50 Pipeline ADCs Using Valine-Citrulline Peptide Linker
Table 4.51 Pipeline ADCs Using Hindered Disulphide Linker
Table 4.52 Pipeline ADCs Using Hydrazone Linker
Table 4.53 Pipeline ADCs Using Maleimidocaproyl Linker
Table 4.54 Pipeline ADCs Using Thioether Linker
Table 4.55 Pipeline ADCs Using Protease Cleavable Peptide Linker
Table 4.56 Pipeline ADCs Using Other Non Cleavable Linker
Table 4.57 Pipeline ADCs Using Furin Cleavable Peptide Linker
Table 5.1 List of Contract Manufacturers and Their Capabilities in ADC Manufacturing
Table 5.2 CMOs offering ADC Conjugation Services
Table 5.3 Full Service Contract Manufacturers for ADCs
Table 6.1 ADC HPAPI: Worldwide CMO Facilities
Table 6.2 ADC Conjugation: Worldwide CMO Facilities
Table 6.3 ADC Fill / Finish: Worldwide CMO Facilities
Table 8.1 Current Development Phase and Expected Launch Year of ADCs in Clinical Development (Phase II and Higher)
Table 9.1 SWOT Analysis of ADC Manufacturing Market
Table 9.2 Companies Providing Site-Specific Conjugation Technology
Table 10.1 ADCs in Clinical Development: Share (%) by Phase of Development
Table 10.2 ADCs in Clinical Development: Share (%) by Cytotoxin Used
Table 10.3 ADC Sales Forecast, 2012 - 2024: Base Scenario (USD MM)
Table 10.4 ADC Sales Forecast, 2012 - 2024: Conservative Scenario (USD MM)
Table 10.5 ADC Sales Forecast, 2012 - 2024: Optimistic Scenario (USD MM)
Table 10.6 ADCs: Relative Cost of Manufacturing
Table 10.7 ADC Contract Manufacturing Market, 2013 - 2024: Base Scenario (USD MM)
Table 10.8 ADC Contract Manufacturing Market, 2013 - 2024: Conservative Scenario (USD MM)
Table 10.9 ADC Contract Manufacturing Market, 2013 - 2024: Optimistic Scenario (USD MM)
Table 10.10 ADC Contract Manufacturing Forecast: Antibody, 2013 - 2024: Base Scenario (USD MM)
Table 10.11 ADC Contract Manufacturing Forecast: Antibody, 2013 - 2024: Conservative Scenario (USD MM)
Table 10.12 ADC Contract Manufacturing Forecast: Antibody, 2013 - 2024: Optimistic Scenario (USD MM)
Table 10.13 ADC Contract Manufacturing Forecast: Drug / Linker, 2013 - 2024: Base Scenario (USD MM)
Table 10.14 ADC Contract Manufacturing Forecast: Drug / Linker, 2013 - 2024: Conservative Scenario (USD MM)
Table 10.15 ADC Contract Manufacturing Forecast: Drug / Linker, 2013 - 2024: Optimistic Scenario (USD MM)
Table 10.16 ADC Contract Manufacturing Forecast: Conjugation, 2013 - 2024: Base Scenario (USD MM)
Table 10.17 ADC Contract Manufacturing Forecast: Conjugation, 2013 - 2024: Conservative Scenario (USD MM)
Table 10.18 ADC Contract Manufacturing Forecast: Conjugation, 2013 - 2024: Optimistic Scenario (USD MM)
Table 10.19 ADC Contract Manufacturing Forecast: Fill / Finish, 2013 - 2024: Base Scenario (USD MM)
Table 10.20 ADC Contract Manufacturing Forecast: Fill / Finish, 2013 - 2024: Conservative Scenario (USD MM)
Table 10.21 ADC Contract Manufacturing Forecast: Fill / Finish, 2013 - 2024: Optimistic Scenario (USD MM)
Table 10.22 ADC Contract Manufacturing Forecast: Other Activities, 2013 - 2024: Base Scenario (USD MM)
Table 10.23 ADC Contract Manufacturing Forecast: Other Activities, 2013 - 2024: Conservative Scenario (USD MM)
Table 10.24 ADC Contract Manufacturing Forecast: Other Activities, 2013 - 2024: Optimistic Scenario (USD MM)

The following companies have been mentioned in the report.

1. AAIPharma Services
2. AbbVie
3. Abgenomics
4. Abbott
5. Aces Pharma
6. Affinicon
7. Allozyne
8. Alkermes
9. Almac
10. Ambrex
11. Amgen
12. AMPAC FINE Chemicals
13. AMRI
14. Arch Pharmalabs
15. ASH Stevens
16. Assymchem Laboratories
17. Astellas Pharma
18. Avid Biologics
19. Baxter Biopharma
20. Bayer Healthcare
21. Ben Venue Laboratories
22. Biotest
23. Bristol-Myers Squibb
24. Cedarburg Hauser
25. Cambrex
26. Carbogen
27. Catalent Pharma Solutions
28. Celldex Therapeutics
29. CEPiA Sanofi
30. Chemcon
31. Chugai Pharma
32. Coldstream Laboratories
33. Corden Pharma
34. CytomX Therapeutics
35. Daiichi Sankyo
36. Dalton Pharma
37. DSM Pharmaceuticals
38. Eli Lilly
39. Endo Pharmaceuticals
40. Esperance Pharmaceuticals
41. Evonik
42. Exela
43. Ferro Pfanstiehl
44. Fujifilm Diosynth Biotechnologies
45. Genentech
46. Genmab
47. Goodwin Biotechnology
48. GP Pharm SA
49. GSK
50. Haupt Pharma
51. Heidelberg Pharma
52. Helsinn Advanced Synthesis
53. IDT Australia Ltd.
54. Igenica
55. ImmunoGen
56. Immunomedics
57. Intellect Neurosciences
58. Lonza
59. Merck
60. Mersana therapeutics
61. Millennium
62. National Research Council, Canada
63. NBE Therapeutics
64. Nicholas Laboratories
65. Novartis
66. Novasep
67. Oncotec Pharma
68. One 2 One
69. OSO Pharmaceuticals
70. Oxford Biotherapeutics
71. Penn Pharmaceutical Services
72. Pfizer
73. Pharmatek
74. PharmIdea
75. PhiloChem
76. Pierre Fabre
77. Piramal Healthcare
78. Polytherics
79. Progenics Pharmaceuticals
80. Redwood Biosciences
81. Roche
82. SAFC
83. Safebridge Consultants
84. Sanofi Aventis
85. ScinoPharm
86. SCM Pharma
87. Seattle Genetics
88. SICOR
89. Sigma-Aldrich
90. Spirogen
91. Stem CentRx
92. Sutro Biopharma
93. Symbiosis Pharma Services
94. Synthon Biopharma
95. Takeda Pharmaceuticals
96. Uman Pharma
97. Viventia Bio
98. Wuxi Pharma Tec
99. Wyeth
100. Zhejiang Medicine Co

To order this report: Antibody Drug Conjugates: Contract Manufacturing Market, 2014-2024
http://www.reportlinker.com/p02016141/Antibody-Drug-Conjugates-Contract-Manufacturing-Market-2014-2024.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Manufacturing

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Is advanced scheduling in Kubernetes achievable? Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, will answer these questions and demonstrate techniques for implementing advanced scheduling. For example, using spot instances ...
SYS-CON Events announced today that Daiya Industry will exhibit at the Japanese Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Ruby Development Inc. builds new services in short period of time and provides a continuous support of those services based on Ruby on Rails. For more information, please visit https://github.com/RubyDevInc.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
Nordstrom is transforming the way that they do business and the cloud is the key to enabling speed and hyper personalized customer experiences. In his session at 21st Cloud Expo, Ken Schow, VP of Engineering at Nordstrom, will discuss some of the key learnings and common pitfalls of large enterprises moving to the cloud. This includes strategies around choosing a cloud provider(s), architecture, and lessons learned. In addition, he’ll go over some of the best practices for structured team migrat...
As businesses evolve, they need technology that is simple to help them succeed today and flexible enough to help them build for tomorrow. Chrome is fit for the workplace of the future — providing a secure, consistent user experience across a range of devices that can be used anywhere. In her session at 21st Cloud Expo, Vidya Nagarajan, a Senior Product Manager at Google, will take a look at various options as to how ChromeOS can be leveraged to interact with people on the devices, and formats th...
First generation hyperconverged solutions have taken the data center by storm, rapidly proliferating in pockets everywhere to provide further consolidation of floor space and workloads. These first generation solutions are not without challenges, however. In his session at 21st Cloud Expo, Wes Talbert, a Principal Architect and results-driven enterprise sales leader at NetApp, will discuss how the HCI solution of tomorrow will integrate with the public cloud to deliver a quality hybrid cloud e...
SYS-CON Events announced today that Yuasa System will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Yuasa System is introducing a multi-purpose endurance testing system for flexible displays, OLED devices, flexible substrates, flat cables, and films in smartphones, wearables, automobiles, and healthcare.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant tha...
Organizations do not need a Big Data strategy; they need a business strategy that incorporates Big Data. Most organizations lack a road map for using Big Data to optimize key business processes, deliver a differentiated customer experience, or uncover new business opportunities. They do not understand what’s possible with respect to integrating Big Data into the business model.
The session is centered around the tracing of systems on cloud using technologies like ebpf. The goal is to talk about what this technology is all about and what purpose it serves. In his session at 21st Cloud Expo, Shashank Jain, Development Architect at SAP, will touch upon concepts of observability in the cloud and also some of the challenges we have. Generally most cloud-based monitoring tools capture details at a very granular level. To troubleshoot problems this might not be good enough.
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, will discuss how from store operations...
As people view cloud as a preferred option to build IT systems, the size of the cloud-based system is getting bigger and more complex. As the system gets bigger, more people need to collaborate from design to management. As more people collaborate to create a bigger system, the need for a systematic approach to automate the process is required. Just as in software, cloud now needs DevOps. In this session, the audience can see how people can solve this issue with a visual model. Visual models ha...
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, will discuss how they bu...
SYS-CON Events announced today that Dasher Technologies will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Dasher Technologies, Inc. ® is a premier IT solution provider that delivers expert technical resources along with trusted account executives to architect and deliver complete IT solutions and services to help our clients execute their goals, plans and objectives. Since 1999, we'v...